Last reviewed · How we verify
Oxaliplatin (OXAL)
Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill rapidly dividing cancer cells.
Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill rapidly dividing cancer cells. Used for Metastatic colorectal cancer (in combination with 5-FU/leucovorin), Adjuvant treatment of stage III colon cancer (in combination with 5-FU/leucovorin), Advanced gastric cancer.
At a glance
| Generic name | Oxaliplatin (OXAL) |
|---|---|
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Drug class | Platinum-based chemotherapy agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Oxaliplatin is a third-generation platinum compound that binds to DNA and forms interstrand and intrastrand crosslinks, preventing DNA replication and transcription. Unlike earlier platinum agents, it has a unique diaminocyclohexane (DACH) ligand that confers activity against some platinum-resistant tumors. It is typically used in combination chemotherapy regimens such as FOLFOX (with fluorouracil and leucovorin).
Approved indications
- Metastatic colorectal cancer (in combination with 5-FU/leucovorin)
- Adjuvant treatment of stage III colon cancer (in combination with 5-FU/leucovorin)
- Advanced gastric cancer
- Non-small cell lung cancer (in combination regimens)
Common side effects
- Peripheral neuropathy (acute and chronic)
- Nausea and vomiting
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Diarrhea
- Fatigue
- Allergic reactions (including anaphylaxis)
Key clinical trials
- Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management (PHASE2)
- Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer (PHASE3)
- Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer (PHASE3)
- Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer (PHASE2)
- Irinotecan or Fluorouracil Plus Leucovorin in Treating Patients With Previously Treated Metastatic Colorectal Cancer (PHASE2)
- Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer (PHASE2)
- Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver (PHASE2)
- Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |